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The management of non-small cell lung cancer (NSCLC) has evolved into a multidiscipli-
nary team approach that traditionally has involved medical oncology, radiation oncology,
and thoracic surgery. However, in the era of personalized medicine the importance of mol-
ecular diagnostics requires adequate tissue for histologic subtyping and molecular testing
and thus requires the engagement of other subspecialties such as pathology, respirology,
and interventional radiology. Unfortunately in 2014, the majority of patients presenting with
NSCLC will succumb to their disease and the early integration of palliative care into the
treatment strategy will improve the quality of life and end-of-life care of our patients and
may in fact improve their overall survival.
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INTRODUCTION
Lung cancer is globally the leading cause of cancer death for both
men and women, more so than colorectal, breast and prostate
cancer combined (1). According to the Canadian Cancer Society’s
statistics 2013 report, lung cancer accounts for approximately 25%
of cancer deaths each year (2). Histologically, the majority of lung
cancers diagnosed are non-small cell lung cancer (NSCLC). The
most important risk factor for developing lung cancer remains
tobacco use, accounting for an estimated 86% of lung cancer cases
in high-income countries like Canada and the median age at diag-
nosis is 70. However, the incidence of lung cancer in non-smoking
young women is increasing (2).
Although there is no data available specifically on NSCLC in
Canada, the National Cancer Institute’s surveillance, epidemiol-
ogy, and end results (SEER) database in the United States has
reported 5-year survival rates across all stages being only 16%, with
stage IIIA, IIIB, and IV at 14, 5, and 1%, respectively (3). Although
post-operative adjuvant treatment, combined-modality treatment
approaches and the newer targeted therapies have improved out-
comes in a subset of patients, NSCLC continues to be diagnosed
late with the majority of patients presenting with advanced stage
IV disease with an associated significant symptom burden. Thus,
the goal of systemic therapy in this setting is to prolong sur-
vival and improve quality of life (QoL) by treating cancer related
symptoms.
Dr. Ellis has previously written an excellent review of the impor-
tance of the multidisciplinary team management of patients with
NSCLC (4). In this review, he addressed such things as diagnos-
tic assessment clinics, multidisciplinary case conferencing, and
involvement of the patient as part of the team as well as psy-
chosocial and nutritional support. Thus, the primary focus of this
review will be on the early integration of palliative care. As well
we will briefly address the rationale for an increased awareness of
recent advances in lung cancer care among the various specialties
involved in the assessment of patients with lung cancer and the
need to establish a cohesive network for ongoing communication
and collaboration.
ONE EXAMPLE OF THE IMPORTANCE OF A COLLABORATIVE
CARE APPROACH TO NON-SMALL CELL LUNG CANCER
Although chemotherapy remains the standard of care for most
patients, there has clearly been a shift toward personalized therapy
with the understanding of molecular diagnosis and treatment of
lung cancer. This has come about by the identification of a num-
ber of actionable mutations including the EGFR and ALK fusion
genes, which have revolutionized therapy in those patients who
harbor these mutations (5–7). As demonstrated by the Lung Can-
cer Mutation Consortium, two-thirds of NSCLC patients have an
oncogenic driver and those patients with these drivers have been
shown to live longer if they receive the corresponding targeted
agent (8).
Unfortunately, the majority of patients present to the medical
oncologist without knowledge of the EGFR or ALK mutation sta-
tus, which has the potential for delaying the start of treatment.
Furthermore, a significant number of patients will be found to
have insufficient tissue to do the appropriate molecular analysis,
which will further delay treatment and often requires commencing
chemotherapy in patients in whom it might be unnecessary thus
exposing them to increased toxicity and an inferior treatment.
Therefore, it is important for physicians involved in the diagnosis
and treatment of lung cancer to be aware that maximizing tissue
yield for histologic subtyping and molecular testing is not only
crucial but also essential to be able to offer patients a personalized
treatment approach.
Thus, an increased awareness of recent advances in lung can-
cer care by engaging multidisciplinary teams in discussions about
innovative knowledge transfer strategies would hopefully lead
to more effective practice. It is also important for professionals
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including respirologists, thoracic surgeons, internal medicine, and
interventional radiologists working with lung cancer patients to
establish a cohesive network for ongoing communication and
collaboration.
INTEGRATION OF EARLY PALLIATIVE CARE
A study examining inoperable NSCLC patients with a good perfor-
mance status found an average of 14.3 symptoms reported by these
patients at presentation. Even patients with a WHO Performance
Status of 0 (fully active) reported an average of 11.6 symptoms.
The most commonly reported symptoms included fatigue, lack of
energy, shortness of breath, cough, worrying, and chest pain (9).
Similarly, a Canadian study conducted in the ambulatory setting
found newly diagnosed lung cancer patients had a greater symp-
tom burden compared to other cancer sites (10). As expected, as
lung cancer progresses, so does the symptom burden. A group of
patients in a community radiation oncology program were found
to have increased symptom severity during the last few months of
their life, compared to the 3-months prior (11). These studies high-
light the importance of early palliative care (EPC) involvement to
help guide symptom management.
Palliative care has also been shown to assist with goals of care
discussions and address psychosocial supports. The WHO now
defines palliative care as “an approach that improves the quality
of life of patients and their families facing the problem asso-
ciated with life-threatening illness, through the prevention and
relief of suffering by means of early identification and impeccable
assessment and treatment of pain and other problems includ-
ing physical, psychosocial, and spiritual.” As well they state “is
applicable early in the course of illness, in conjunction with other
therapies that are intended to prolong life, such as chemotherapy
or radiation therapy, and includes those investigations needed to
better understand and manage distressing clinical complications”
(12). Patients report inadequate communication with providers
about shared decision-making at the end-of-life (EOL). This bet-
ter understanding of their illness through important conversations
can help patients and families prepare for EOL, which they have
reported as a valuable aspect of their care. In fact, patients rely on
their physicians to discuss hospice, advanced directives, and other
EOL care options. Studies have shown deficiencies in the area of
communication surrounding EOL (13, 14) and palliative care can
assist in facilitating these important discussions.
The American Society of Clinical Oncology published a pro-
visional clinical opinion in 2012 recommending the integration
of palliative care into standard oncology care for patients with
metastatic cancer. This recommendation was based on a phase III
clinical trial conducted by Temel and colleagues of 151 ambulatory
patients newly diagnosed with NSCLC. Patients were randomly
assigned to standard oncology care or EPC. The primary out-
come was QoL at 12 weeks, with secondary outcomes including
mood, understanding of illness, and aggressiveness of care at the
EOL. Both QoL and depression had significantly improved with
EPC. In addition, patients in the intervention group had higher
documentation rates of resuscitation preferences, as well as less
aggressive care at EOL, including intravenous chemotherapy in the
last 2 weeks of life. Despite this, patients who received EPC had a
significantly prolonged survival, by approximately 3 months (15).
A recent review by Irwin et al. postulated the possible mech-
anisms for prolonged survival attributed to EPC in patients with
metastatic NSCLC. They identified four randomized controlled
trials, including the Temel study above, which studied palliative
care interventions’ effects on QoL and EOL care in cancer patients.
They all found improved QoL in patients who received EPC, and
two of the studies showed increased survival in the intervention
groups. Irwin and colleagues hypothesized several variables are
associated with increased survival in this population based on cur-
rent literature (16). The first being palliative care’s focus on reliev-
ing suffering and improving symptom distress. Both health-related
QoL and physical symptoms have been associated with prognosis
(17, 18). Secondly, they identified treating depression as a poten-
tial mechanism for improved survival. The relationship between
depression and survival may be due to multiple effects. Improving
depression may have a beneficial impact on health behaviors linked
to treatment adherence and well-being. Depression is known to
activate the hypothalamic–pituitary axis and thus increase levels
of cortisol, affecting the immune system and specifically, helper T
cells (19, 20). A third mechanism identified is EPC’s focus on dis-
ease/prognosis understanding and goals of care discussions. When
patients had a better understanding of their prognosis, they were
less likely to receive chemotherapy at EOL. Many believe that there
is a point at EOL where the toxicity of chemotherapy may has-
ten death. Temel et al. found patients assigned to EPC were less
likely to receive intravenous chemotherapy at EOL and the interval
between last chemotherapy infusion and time of death was longer
for patients who received EPC compared to those who did not
(16). Finally, the focus on increasing social support for both the
patient and their caregivers may also be a factor in extending length
of survival. Many studies have demonstrated that marital status
is associated with a survival advantage for lung cancer patients,
which may translate into increased social support (21, 22).
In a more recent retrospective study, Hui and colleagues (23)
looked at the impact, timing, and setting of palliative care refer-
rals on the quality of end-of-life in cancer patients. A total of 366
adult cancer patients at a tertiary care center who between Sep-
tember 1, 2009 and February 28, 2010 who received a palliative
care referral and who had contact with the cancer center within
the last 3 months of life were included in the study. Outpatient
referrals were associated with significantly fewer emergency room
visits, hospital admissions, hospital deaths, ICU admissions, and
a shorter duration of hospital stay, when compared to inpatient
referrals. Outpatient palliative care referral remained an indepen-
dent factor for improved end-of-life care in multivariate analysis.
It is noteworthy that 20% of patients in each group had a diag-
nosis of lung cancer. Early outpatient involvement with palliative
care allows patients to develop a longitudinal therapeutic rela-
tionship. Through the course of multiple clinic visits the palliative
care team can help facilitate goals of care discussions and advanced
care planning, with the hope of reducing aggressive interventions
at EOL. The palliative care team also has access to community
resources and supports for both the patient and their families as
their disease progresses. Finally, the palliative care focus on symp-
tom assessments not only improves QoL but can also minimize
unnecessary ER or hospital admissions with patient education and
routine follow-up for symptom management (23).
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CONCLUSION
Clearly, our ultimate goal is to improve the diagnosis and care of
lung cancer patients. The treatment of NSCLC has evolved con-
siderably including the introduction of post-operative adjuvant
therapy for early stage disease and the use of combined-modality
therapy for stage III disease that requires the collaboration of
medical oncology, radiation oncology, and thoracic surgery. The
management of advanced disease has also evolved significantly
and a personalized approach to treatment in advanced stage IV
disease is a reality. Although traditionally, collaboration has pri-
marily been between thoracic surgery, radiation oncology, and
medical oncology, in the era of personalized medicine it is impor-
tant for all physicians involved in the diagnosis and treatment of
lung cancer to be aware that maximizing tissue yield for histo-
logic subtyping and molecular testing is not only crucial but also
essential to be able to offer patients the appropriate therapy in
a timely fashion. Unfortunately in 2014, the majority of patients
presenting with NSCLC will succumb to their disease and studies
have shown that the early integration of palliative care into the
management strategy will improve the QoL and EOL care of our
patients.
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